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Summary
The HR2 haplotype of the factor V gene, which contains the histi-
dine to arginine Substitution at position 1299, has been reported to be
associated with reduced factor V levels. Because high factor V levels
have been found to be associated with an increased risk of myocardial
infarction, we examined how the presence of the R2 allele affected the
risk of myocardial infarction in the case-control "Study of Myocardial
Infarctions Leiden".
Among 560 men with a first myocardial infarction before the age of
70 years, 9.5% were heterozygous carriers of the R2 allele. The control
group consisted of 646 men, in which 9.9% were heterozygous and
0.2% homozygous carriers of the R2 allele. The risk of myocardial
infarction in the presence of the R2 allele was not increased (odds ratio,
0.9; 95% confidence interval 0.6 to 1.4). Exclusion of factor V Leiden
carriers did not change this result. The risk was 4.4-fold increased for
smokers who carried the R2 allele compared to non-smoking non-
carriers. No synergy was found between metabolic risk factors and the
presence of the R2 allele.
We conclude that the risk of myocardial infarction for men in the
presence of the R2 allele of the Hisl299Arg polymorphism is neither
increased nor decreased.
Introduction
Coagulation factor V can be activated by factor Xa or by thrombin.
Activated factor V (factor Va) is an essential cofactor of factor Xa in
the conversion of prothrombin to thrombin. Activated protein C (APC)
limits the formation of thrombin by proteolytic cleavage of the co-
factors Va and Villa, and thereby acts äs an anticoagulant. Resistance
to APC is associated with an increased risk of venous thrombosis (1,2).
A few studies reported on the risk of myocardial infarction and found
no increased risk (3-5). Most cases of APC-resistance are caused by the
presence of factor V Leiden, a single point mutation in the factor V
gene (Arg506Gln) (6). This mutation is common and increases the risk
Correspondence to: Prof. Dr. F.R. Rosendaal, Clinical Epidemiology, Bldg
l CO-P, Leiden University Medical Center, P.O. Box 9600, 2300 RC Leiden,
The Netherlands - Tel.: +31-71-5264037; Fax: +31-71-5248122; E-mail:
F.R.Rosendaal @ lumc.nl
of venous thrombosis considerably (7,8). In contrast, studies on the risk
of coronary artery disease in the presence of factor V Leiden are in-
consistent, showing a slightly increased risk (9-11) or no excess risk at
all (8,12).
Reduced sensitivity for APC not due to factor V Leiden is also asso-
ciated with an increased risk of venous thrombosis (13). In 1997 a
specific haplotype of factor V was reported, which may contribute to an
APC-resistant phenotype. This so-called HR2 haplotype contains a
histidine to arginine Substitution at position 1299 (Hisl299Arg) in the
B-domain of factor V (14). The Argl299 allele (R2 allele) was found to
be associated with partial factor V deficiency in an Italian population
(15). In a French study patients with venous thrombosis who carried the
R2 allele had significantly lower circulating factor V levels than non-
carriers and the risk of venous thrombosis in carriers of the HR2 haplo-
type was 1.8-fold increased (16). However, in the original study in
which the haplotype was reported no increased risk of venous thrombo-
sis was found, nor an association of the R2 allele with reduced factor V
levels (14). Factor V activity evaluated in five patients and nine control
subjects who carried the R2 allele was considered normal (14) In a
study among family members of probands with at least one episode of
deep vein thrombosis or pulmonary embolism and an inherited defect
(antithrombin, protein C or protein S deficiency, factor V Leiden or the
G20210A Variation in the prothrombin gene) none of the members
carrying only the R2 allele developed venous thrombosis (17) In the
"Leiden Thrombophilia Study" (LETS) the risk of deep-vein thrombo-
sis in the presence of this allele was not increased (18). Reduced levels
of factor V antigen in patients äs well äs in control subjects were found
in carriers of the R2 allele. In the LETS we showed the absence of an
association between factor V levels and risk of thrombosis (19) The
mechanism by which the R2 allele is associated with reduced factor V
levels is not yet known; the Hisl299Arg polymorphism could be in
linkage disequilibrmm with another polymorphism in the factor V gene
or the variant itself could be responsible for reduced levels Recentlv
it has been reported that in carriers of the R2 allele the ratio of the twö
isoforms of factor V (factor VI and factor V2) is shifted in favour of
the factor VI form, which might lead to a higher procoagulant activitv
(20,21). *
It has been suggested that the risk of myocardial infarction in sub
jects with high levels of factor V activity was higher than in those with
low levels (12). Thus, if carriership of the R2 allele is associated with
low factor V levels (15, 16, 18), one might expect carriers to have a
lower risk of myocardial infarction than non carriers. So far only one
study reported on the risk of arterial thrombosis in the presence of the
R2 allele (22); however, the results seem to be in contrast with what we
would expect on the basis of the aforementioned hypothesis We
studied the association of the Hisl299Arg polymorphism with myocar
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Table l Genotypes and allele frequencies of factor V Hisl299Arg (H1299R)
polymorphism in patients and control subjects





















































denotes odds ratio of H-R/R-R versus H/H
dial infarction in the population-based case-control "Study of Myo-
cardial Infarctions Leiden" which includes 560 men with a first myo-
cardial infarction and 646 control subjects.
Patients and Methods
Patients and Control Subjects
Details of the "Study of Myocardial Infarctions Leiden" have been describ-
ed elsewhere (10). Briefly, patients were men below the age of 70 with a first
myocardial infarction that occurred between January 1990 and January 1996.
The control group also consisted of men, frequency matched on age to the pa-
tients. They had undergone an orthopedic Intervention between January 1990
and May 1996 and had received prophylactic anticoagulants for a short period
after the Intervention. Both patients and control subjects were born in the
Netherlands. The study protocol was approved by the Ethic Committee.
All persons completed a questionnaire concerning the presence of cardio-
vascular risk factors such äs smoking habits, obesity, diabetes, hypertension
and hypercholesterolemia. For patients all questions referred to the period
before their myocardial infarction. The Quetelet index was derived by dividing
weight (kilograms) by squared height (meters2). Persons were considered
obese if their Quetelet index exceeded 30 kg/m2. Medication use and history of
diabetes were ascertained in an interview with control subjects and retrieved
from discharge letters for the patients. A person was classified äs hypertensive
or hypercholesterolemic when he was taking prescription drugs for these con-
ditions. The variables obesity, diabetes, hypertension and hypercholesterolemia
were grouped together äs "metabolic risk factors".
Blood Collection and DNAnalysis
A morning fasting blood sample was drawn from the antecubital vein in
0.1 volume 0.106M trisodium citrate using Sarstedt Monovette® tubes. We
separated the blood sample into plasma and cells by centrifugation. High mole-
cular weight DNA was extracted from the white blood cells by a salting-out
procedure (23). The DNA was stored at 4° C until amplification. Analyzable
DNA was available for 560 patients and 646 control subjects.
The detection of the His 1299Arg polymorphism (4070 A -> G) (numbering
according to Jenny et al. [24]) in the factor V gene was performed by polyme-
rase chain reaction (PCR) followed by restriction enzyme digestion. A 1568 bp
fragment was amplified with primer A (S'-TGCTCCTTTATCTCCGAG-
GACC-3') and primer B (5'-CTCTGGAGGAGTTGATGTTTGTCC-3'). The
PCR mixture consisted of 4 ng of both oligonucleotides, 250 μΜ of each
dNTP, 67 mM Tris-HCl pH 8.8, 6.7 mM MgCl2, 10 mM ß-mercaptoethanol,
6.7 μΜ EDTA, 16.6 mM (NH4)2S04, 0.5 mg/ml BSA, 0.2 units AmpliTaq
polymerase (Perkin-Elmer) and 10% DMSO in a total volume of 10 μΐ. The re-
actions were performed in an Amplitron II (Thermolyne). The PCR conditions
were äs follows: 4 min initial denaturation at 91° C, followed by 35 cycles of
l min at 91° C, l min at 63° C and 3 min at 71° C. A final extension was per-
formed at 71 ° C for 4 min. PCR products were digested by incubation with Rsal
(New England Biolabs) at 37° C for 2 h. The restriction fragments (1438 and
130 bp for the 4070A [Hisl299] allele, and 862,576 and 130 bp for the 4070G
allele [Argl299, R2 allele]) were separated in l .3% agarose gels and visualized
after ethidium bromide staining. Genetic analysis of factor V Leiden (1691 G
—> A) Status was performed äs previously described (6).
Statislical Analysis
An odds ratio (OR) was calculated äs a measure of relative risk. This odds
ratio estimates the risk of a myocardial infarction in the presence of the R2
allele relative to the absence of the R2 allele, the reference category (i. e. non-
carriers). A 95% confidence interval (95% CI) was calculated according to the
method of Woolf (25). This interval indicates the ränge of plausible values for
the odds ratio taking chance Variation into account. Multiple logistic regression
was performed to adjust for age. Confidence intervals for the adjusted odds
ratios were calculated using the Standard errors of the coefficients estimated by
maximum likelihood methods. Means are presented with Standard deviation
(s.d.).
Results
The characteristics of all patients and control subjects have been de-
scribed before (10). The mean age of patients was 56.2 (s.d. 9.0) years
and of control subjects 57.3 (s. d. 10.8) years. Risk factors äs smoking,
obesity, diabetes, hypertension and hypercholesterolemia were more
often found in patients man in control subjects, with the most striking
contrast in younger persons.
The frequency of the R2 allele was 4.7% in patients and 5.1% among
control subjects. In 53 out of 560 (9.5%) patients the heterozygous
genotype of the His 1299Arg variant was detected compared to 64 in
646 control subjects (9.9%). Only one homozygous carrier, a control
subject 46 years old, was found. The relative risk of myocardial infarc-
tion associated with R2 allele carriership was 0.9 (95% CI 0.6 - 1.4)
(Table 1). In the subgroup of 314 men aged less than 50 no increased
risk was found [OR 1.0 (95% CI 0.5 - 2.3)]. The risk among persons
aged 50 years or more was not increased either [OR 0.9 (95% CI 0.6 to
1.4)].
Exclusion of carriers of factor V Leiden (38 patients and 32 control
subjects), resulted in an odds ratio of 0.9 (95% CI 0.6 - 1.4) for R2
carriers compared to non-carriers, again not indicative of an increased
risk (Table 2). Among smokers R2-carriers had a 4.4-fold increased
risk compared to non-smoking non-carriers. In comparison, smokers
without the R2 allele had a relative risk of about three. The risk among
persons with major metabolic risk factors was similar for those with or
without the R2 allele, relative to persons without any of these risk
factors.
Discussion
This population-based case-control "Study of Myocardial Infarc-
tions Leiden" shows that the factor V His 1299Arg polymorphism is not
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Table 2 Risk effect of Risk factor
factor V Leiden sm^king
, , , · ' · , r No factor V Leidenand a metabolic nsk factor,
without and with the factor
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Odds Ratio (95 % CI) t
1
0 9 (0 6 - 1 4)
1 4 (0 8 - 2 3)
2 3 (0 2 - 65 2)
1
0 8 (0 4 - 1 4)
3 2 ( 2 4 - 4 1)
4 4 (2 2 - 8 7)
1
1 0 (0 6 - 1 6)
1 3(1 0-1 7)
1 2 (0 6 - 2 4)
* percentages are calculated withm each stratum of cardiovascular nsk factor, i e among the persons without factor V Leiden 9 8 % of patients were
carners of the R2 allele of factor V Hisl299Arg
t reference categones are non-R2 carners without the particular risk factor
associated with the risk of myocardial infarction. In patients 9.5% were
carrier of the R2 allele compared to 10.1% in control subjects, resulting
in an odds ratio of 0.9 (95% CI 0.6 -1.4) indicating no increased risk.
The allele frequency of 5.1% among our control subjects corre-
sponds with an allele frequency of 4.1% found in healthy persons frorn
the Dutch "Leiden Thrombophilia Study" (18) and with 5.8% found
among 398 healthy subjects from France (16). Among Italian subjects
the frequency seems a little bit higher; allele frequencies of 8.0% (14)
and 7.5% have been found (15).
The risk of myocardial infarction in the presence of the R2 allele is
not increased in our study, which is in contrast to an Italian case-control
study in which a two-fold increased risk of coronary artery disease was
found. The prevalence of the R2 allele was also increased in patients
who experienced a myocardial infarction (22). As this study included
mainly elderly patients, this might explain the difference with our re-
sults. However, when we restricted the analysis to patients between 50
and 70 years of age we did not find an increased risk for carriers of the
R2 allele. The Italian study reported an increased risk for non-smoking
carriers, which could not be confirmed in our study.
Our results on the risk of myocardial infarction in the presence of the
R2 allele of the His 1299Arg polymorphism are comparable with most,
but not all, studies on venous thrombosis. In three different studies on
venous thrombosis no increased risk was found at all (14, 18, 26),
while in a study in France an almost two-fold increased risk for carriers
of the R2 allele was described (16). The risk of myocardial infarction or
venous thrombosis in the presence of a particular mutation involved in
the coagulation cascade are often different. For example, results of
studies in which the factor V Leiden mutation was examined äs a
potential risk factor for myocardial infarction are inconsistent (8,10-12),
whereas the risk of venous thrombosis is indisputably increased (l, 8).
In several studies the risk of myocardial infarction for a prothrom-
botic mutation is highly increased in the presence of an established car-
diovascular risk factor (10-12). Therefore, we considered the presence
of synergy in our present study, i.e. interaction between cardiovascular
risk factors and the His 1299Arg polymorphism. We found no synergy
between metabolic risk factors and the presence of the R2 allele.
Although the risk for smokers with the R2 allele was 4.4-fold increased,
the confidence intervals in these analyses were too wide to allow any
conclusions about synergy.
Only three individuals carried both the factor V Leiden mutation and
the R2 allele of the His 1299Arg polymorphism and therefore this study
offers little Information on the risk for carriers of both variants. In a
study of venous thrombosis among 810 family members of probands
with at least one venous thromboembolism and an inherited defect,
23 persons carried both variants (17). In these selected family members
the relative risk of venous thrombosis associated with factor V Leiden
increased from 4.2 to 10.9 when the R2 allele was also present. The
authors suggested that the prothrombotic action of the R2 allele could
be mediated through an enhancement of resistance to APC, synergistic
with that caused by factor V Leiden (17). These results could be
confirmed in the "Leiden Thrombophilia Study" (18).
Recently, a polymorphism in exon 25 (A6755G) of the factor V
gene was detected, causing the Substitution of asparagine by glycine at
Position 2194, at the end of the C2 domain of factor V. It was found to
be tightly linked to the R2 allele of the Hisl299Arg polymorphism (22).
Among 117 heterozygous carriers of the R2 allele in our study all, but
two, were also heterozygous carriers of the Gly2194 allele. The homo-
zygous carrier of the R2 allele was also a homozygous carrier of the
Gly2194 allele. These results confirm the tight linkage between the R2
allele and the Gly2194 allele, äs has been described before (18,21).
In conclusion, the risk of myocardial infarction for men in the
presence of the R2 allele of the His 1299Arg polymorphism is neither
increased nor decreased.
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